Joles Nation
Monday, September 11, 2017
Longer Progression-Free Survival for Durvalumab in NSCLC
Longer median progression-free survival from randomization, higher response rate with durvalumab Longer Progression-Free Survival for Durvalumab in NSCLC
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment